Markers to Determine Arrhythmia Vulnerability in End Stage Heart Failure.

Published: 12-03-2012
Last updated: 26-04-2024

The main objective is to find markers for arrhythmia vulnerability in patients with end stage heart failure.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Cardiac arrhythmias
Study type	Observational invasive

Summary

ID

NL-OMON39922

Source
ToetsingOnline

Brief title
Arrhythmia vulnerability in heart failure, AVES-HF

Condition

- Cardiac arrhythmias

Synonym
arrhythmia, heart failure, reduced heart function

Research involving
Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: arrhythmia, heart failure, vulnerability

Outcome measures

Primary outcome

Measurements of the electrophysiological, structural and (immuno) histological

characteristics of mature ventricular cardiomyocytes and serum markers.

Secondary outcome

Potential electrical markers and biomarkers for arrhythmia vulnerability.

Study description

Background summary

In patients with congestive heart failure (CHF) a major cause of mortality is sudden cardiac death (SCD). A large amount of studies has been conducted to investigate determinants of increased susceptibility to SCD, yet the mechanism remains obscured.
Therefore this study will focus on the analysis of electrophysiological, structural, (immuno) histological parameters and serum proteins in patients with end stage heart failure to determine markers for arrhythmia vulnerability.

Study objective

The main objective is to find markers for arrhythmia vulnerability in patients with end stage heart failure.

Study design

This is an observational study.

Study burden and risks

Inclusion in the study does not bring additional burden or risk for these patients.

Contacts

Public

Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ
NL
Scientific
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Patients will be included if they are over 18 years and under 80 years and able to give informed consent.
Patients with end stage heart failure undergoing LVAD implantation.

Exclusion criteria

Under 18 and over 80 years
The inclusion criteria includes only the study population.

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Basic science

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	15-01-2013
Enrollment:	20
Type:	Actual

Ethics review

Approved WMO

Date:	12-03-2012
Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL39545.018.12